Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
HOTH 
Hoth Therapeutics Inc (HOTH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: HOTH (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -84.39% | Avg. Invested days 48 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.97M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 2 | Beta 0.64 | 52 Weeks Range 0.66 - 2.79 | Updated Date 11/6/2025 |
52 Weeks Range 0.66 - 2.79 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.04 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -62.11% | Return on Equity (TTM) -104.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 11691300 | Price to Sales(TTM) - |
Enterprise Value 11691300 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA 0.4 | Shares Outstanding 13259027 | Shares Floating 12705463 |
Shares Outstanding 13259027 | Shares Floating 12705463 | ||
Percent Insiders 4.17 | Percent Institutions 1.89 |
Upturn AI SWOT
Hoth Therapeutics Inc
Company Overview
History and Background
Hoth Therapeutics, Inc. is a biopharmaceutical company focused on developing new therapies for unmet medical needs, including dermatological disorders and other immune-mediated diseases. Founded in 2017, it has focused on identifying and developing promising therapeutic candidates.
Core Business Areas
- Dermatology: Development of therapies for dermatological conditions such as atopic dermatitis (eczema).
- Autoimmune Diseases: Exploration of treatments for autoimmune and inflammatory diseases.
- Drug Development: Research and development of novel therapeutic candidates.
Leadership and Structure
The leadership team consists of experienced professionals in the biopharmaceutical industry. The organizational structure is typical of a small biotech company, focused on research, development, and clinical trials.
Top Products and Market Share
Key Offerings
- HT-001 (Atopic Dermatitis): A topical formulation being developed for atopic dermatitis. Clinical trials are underway. Competitors include Sanofi (SNY) with Dupixent and numerous generic topical corticosteroids.
- HT-KIT (KIT Inhibitor): Targeting mast cell-related disorders. Preclinical stage. Potential competitors include Blueprint Medicines (BPMC).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and regulated. Companies focus on developing and commercializing new drugs. Dermatology and autoimmune disease therapeutics represent large and growing markets.
Positioning
Hoth Therapeutics is a small, early-stage player focusing on niche areas within dermatology and autoimmune diseases. Its competitive advantage lies in its novel therapeutic candidates.
Total Addressable Market (TAM)
The global atopic dermatitis market is estimated to be billions of dollars. Hoth is positioned to capture a portion of this market if its therapies are successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Early-stage development risk
- Reliance on successful clinical trials
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
Threats
- Clinical trial failures
- Competition from larger pharmaceutical companies
- Regulatory hurdles
- Funding constraints
Competitors and Market Share
Key Competitors
- SNY
- BMY
- MRK
Competitive Landscape
Hoth faces significant competition from larger, established pharmaceutical companies with greater resources and broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Growth is dependent on progressing its therapeutic candidates through clinical trials.
Future Projections: Future growth depends on successful clinical trials and potential partnerships.
Recent Initiatives: Focus on advancing HT-001 and HT-KIT through preclinical and clinical development.
Summary
Hoth Therapeutics is an early-stage biopharmaceutical company with promising therapeutic candidates, particularly in dermatology. Its success hinges on positive clinical trial results and securing partnerships to support its research and development efforts. Financial resources are limited, posing a challenge to long-term growth. Competition from larger pharmaceutical companies is a significant threat.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
- Financial News Outlets
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may not be entirely accurate or complete. Investment in biotech companies is inherently risky.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hoth Therapeutics Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2019-02-15 | Founder, President, CEO & Chairman Mr. Robb Knie | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2 | Website https://hoththerapeutics.com |
Full time employees 2 | Website https://hoththerapeutics.com | ||
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; and HT-004 for treatment of asthma and allergies using inhalational administration. The company is developing BioLexa Platform, a proprietary, patented, drug compound platform in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. The company was incorporated in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.